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Biocompatible functionalized carbon 
nanotubes
Carbon nanotubes (CNTs) are firstly 
described by Iijima in early nineties as nee-
dle-like tubes composed of layers of graphitic 
sheets [1]. Either single-walled or multiwalled 
carbon nanotubes (SWNTs or MWNTs), 
made of one or several layers of graphene, 
have been utilized mainly in industry due to 
their characteristic high mechanical strength, 
good electronic and thermal properties [2]. 
Together with the large surface area, the rela-
tively low weight makes them ideal particu-
larly for applications in neuroengineering [3]. 
However, due to the hydrophobic nature, 
pristine CNTs cannot be functionally inte-
grated into biological systems unless they 
undergo surface fictionalization to become 
more biocompatible. Many approaches have 
been developed to alter the inert property of 
CNTs either through covalent (e.g., oxida-
tion and chemical conjugation) or noncova-
lent (e.g., coating with hydrophilic or bio-
logical molecules) strategies [4]. Since then, 
functionalized CNTs ( f-CNTs), possessing 
reduced cytotoxicity, have received tremen-
dous attention as nanomaterials in bio-
medicine. In particular, f-CNTs held great 
promise as drug or gene carriers in vitro and 
in vivo [5,6].
Studies of carbon nanotubes in brain 
for therapeutic applications
The journey for f-CNTs, serving as drug- and 
gene-delivery vectors, starts with their cel-
lular internalization. Entering cells through 
macropinocytosis was proposed by Bhat-
tacharta et al. as accumulation of SWNT-
DNA hybrids in vacuoles was observed in 
human umbilical vein endothelial cells by 
transmission electron microscopy (TEM) [7]. 
It has also been found that f-CNTs can 
directly penetrate cell membranes in an 
energy-independent manner possibly due to 
their ‘needle-like’ structure [8,9]. Delivering 
drugs into brain is rather challenging and 
is greatly limited due to the presence of the 
blood–brain barrier (BBB) [10]. Nevertheless, 
many studies have demonstrated the success 
of using f-CNTs for brain delivery. Some of 
the important studies are discussed in the 
following paragraphs.
Two recently published studies have 
documented the capability of f-CNTs to 
cross the BBB using in vitro models. Shitya-
kov et al. assessed the dynamic transport 
of FITC-labeled MWNTs across immor-
talized murine microvascular cEND cells 
using the Transwell® device (Corning Inc., 
NY, USA) [11]. The accumulation of FITC-
MWNTs in cells over time was imaged by 
fluorescence and phase-contrast microscopy. 
The transcellular distribution of FITC-
MWNTs was 3D reconstructed using 
dynamics simulation modeling software. 
FITC-MWNT aggregates were nonfluores-
cent and localized on the cell surface while 
more dispersed FITC-MWNTs were located 
intracellularly or associated with cell mem-
brane. Although fluorescence microscopy 
could provide information on the temporal 
and spatial cellular distribution of fluores-
cently labeled f-CNTs, fluorescence was 
likely to be quenched when f-CNTs formed 
agglomerates. TEM is therefore considered to 
be the gold standard method to examine the 
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interaction of f-CNTs with cells by visualizing f-CNTs 
at an ultrastructural level. Another study, conducted 
in our laboratory, investigated the penetration prop-
erties of amino-functionalized MWNTs (MWNT-
NH
3
+) using a co-culture Transwell in vitro BBB 
model comprising of primary porcine brain endothe-
lial cells and primary rat astrocytes [12]. The primary 
porcine brain endothelial cells crossing and the cellular 
uptake by astrocytes were directly observed by TEM. 
MWNT-NH
3
+ accumulation in endocytic vesicles and 
the reduced uptake following 4°C treatment together 
confirmed the involvement of energy-dependent cel-
lular uptake. The transcytosis process was quantified 
by γ-scintigraphy using radiolabeled MWNT-NH
3
+ in 
which maximum transport of 13% of MWNT-NH
3
+ 
was achieved after 72 h incubation.
f-CNTs have contributed to therapeutic strategies 
against different neuropathological disorders in vivo 
including Alzheimer disease [13], glioblastoma [14,15] 
and stroke [16,17]. The first observation of f-CNTs in 
brain was reported by Yang et al. where shortened 
SWNTs were given orally to mice daily for 10 days [13]. 
SWNTs were taken up by absorptive cells and macro-
phages in the intestinal wall but were also detected in 
other organs such as liver, brain and heart. SWNTs 
were observed in lysosomes of neurons and neurites 
by TEM. Furthermore, such SWNTs were able to 
deliver acetylcholine, which was physically mixed 
with SWNTs, leading to improvement in the learning 
and memory capability of an experimentally induced 
Alzheimer disease mouse model.
Stereotactic delivery of f-CNTs into the brain is 
the most common technique used in the early stud-
ies involving f-CNTs. Zhao et al. utilized f-CNT to 
deliver an immunoadjuvant CpG, leading to an anti-
glioma effect [14]. f-CNTs conjugated to CpG oligo-
nucleotides were fluorescently labeled with Cy5.5 and 
were injected intratumorally (it.) into an intracranial 
GL261 glioma. It was found that f-CNT enhanced 
the uptake of CpG in GL261 tumor cells, as detected 
by FACS, resulting in elevated levels of proinflamma-
tory cytokines and reduced tumor growth. Lee et al. 
reported that amine-modified SWNT (a-SWNT) has 
the potential to protect neurons from injury using a rat 
stroke model [17]. Rats were given a-SWNTs via lat-
eral ventricle injection before the induction of stroke. 
a-SWNTs-treated animals were found to have smaller 
infarct regions in the brain compared with the PBS-
treated group. a-SWNTs-treated animals performed 
better in the behavioral functions, assessed by Rota-
Rod treadmill test, indicating the enhancement of 
recovery from stroke injury. The work conducted by us 
further demonstrated that f-CNTs can deliver thera-
peutic Caspase-3 siRNA into brain using a rat stroke 
model. f-CNTs-mediated delivery of siCas3 via corti-
cal injection successfully improved the antiapoptotic 
effect in the endothelin-1-induced stroke model, which 
was accompanied with promoted functional motor 
recovery. Internalization of f-CNTs by neuron cells 
were also observed by TEM at 48 h after injection.
Concerns have been raised whether there are 
adverse effects and inflammatory responses induced 
as a consequence of the intracranial injection itself 
and the introduction of f-CNTs into the brain. It 
is also important to understand the fate of f-CNTs 
after interaction with neuronal tissues, following ste-
reotactic injection. We have investigated the in vivo 
biodegradation of f-CNTs by TEM [18], and also com-
pared two types of f-CNTs in terms of their distribu-
tion patterns in relation to the possible inflammatory 
reactions [19] after stereotactic injection. TEM images 
revealed that f-CNTs were taken up by different neu-
ral cells (e.g., microglia, neurons and astrocytes) and 
the cellular internalization patterns differed between 
f-CNTs with different fictionalization. Structural 
deformation of f-CNTs inside cells was observed as 
early as 48 h postinjection and some tubes suffered 
severe decomposition with complete loss of cylindrical 
structural features. f-CNTs with different fictional-
ization strategies exhibited varied levels of proinflam-
matory cytokines but all at significantly low levels. 
The results together once again demonstrated the bio-
compatibility of f-CNTs which is a requirement of a 
delivery vector.
While stereotactic injection offers precise and direct 
access to the brain, its unfavorable invasive nature ren-
ders necessary the need for a systemic administration 
route to facilitate clinical translation of f-CNTs. Also, 
taking advantage of the various adsorptive-mediated 
or receptor-mediated transcytosis pathways existing in 
BBB, researchers have attempted to develop f-CNTs 
tagged with a brain-targeting ligand to improve brain 
delivery after intravenous injection. Ren et al. devel-
oped dual-targeting f-CNTs that carry the brain target-
ing ligand, Angiopep-2 (ANG) as well as the antican-
cer drug doxorubicin (DOX) [15]. Oxidized MWNTs 
(O-MWNTs) were coated with polyethylene glycol 
(PEG) with ANG conjugated to its terminal. DOX 
was adsorbed MWNT sidewalls. Mice were intrave-
nously injected with those f-CNTs, and an enhanced 
brain uptake of DOX-O-MWNTs-PEG-ANG was 
“While stereotactic injection offers precise 
and direct access to the brain, its unfavorable 
invasive nature renders necessary the need for a 
systemic administration route to facilitate clinical 
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observed compared with non-ANG and DOX alone 
counterparts, measured by DOX fluorescence in iso-
lated brains. DOX-O-MWNTs-PEG-ANG increased 
the median survival time the most. Direct and quan-
titative measurements of f-CNTs uptake in the brain 
or tumor was however not available in this study. A 
recent study from our group has examined quantita-
tively the in vivo biodistribution of f-CNTs and the 
brain uptake following intravenous injection using 
γ-scintigraphy [12]. Capillary depletion confirmed the 
presence of MWNT-NH
3
+ in brain capillaries and also 
parenchyma. The radiolabeled MWNT-NH
3
+ under 
investigation exhibited intrinsic properties to cross 
BBB both in vitro and in vivo. The results thus pave the 
way for future applications of f-CNTs as nanocarriers 
for brain delivery.
Unlike the conventional delivery, other strategies 
involving the innate immune system have been explored 
to deliver f-CNTs to tumor [20,21]. PEGylated SWNTs 
were conjugated to an RGD ligand against integrin 
α
v
β
3
 expressed on the surface of tumor blood ves-
sels [20]. SWNT conjugates were fluorescently labeled 
with Cy5.5, allowing the detection of SWNTs in blood 
samples and tumor tissues using FACS and intravi-
tal fluorescence microscopy, respectively. Following 
intravenous injection, a certain subset of monocytes 
was identified to engulf high amount of SWNTs, and 
such selective SWNT-enriched monocytes were found 
to infiltrate into tumor interstitium. Another study 
was carried out by intratumoral injection of MWNT, 
tagged with a fluorescent probe PKH26, using the 
GL261 glioma model [21]. Most MWNTs (75%) were 
phagocytosed by the tumor macrophages, microglia, 
and 30% microglia were found to be MWNT-positive 
at 24 h after injection. The presence of MWNTs in 
glioma was confirmed by immunohistochemistry at 48 
h postinjection. The above-mentioned immune-based 
delivery accounts for another approach to enhance 
tumor delivery of f-CNTs.
To summarize, CNTs are considered as one of the 
most promising nanomaterials as drug and gene deliv-
ery carriers and there are increasing numbers of stud-
ies documented on the use of functionalized CNTs for 
brain delivery. Results so far have shown that proper 
fictionalization is essential to yield biocompatible 
CNTs which are able to deliver either drugs or genes 
into brain through local or systemic injection. Future 
work should focus on better understanding of the inter-
action of f-CNTs with the BBBs and neural tissues, 
and the uptake mechanisms taking place. Such infor-
mation is beneficial for the design and development of 
f-CNTs-based delivery system, offering efficient and 
specific targeting delivery into brain.
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